// App-Quantinova.ai

e14020 : Discontinuation of everolimus due to unrelated adverse events in cancer patients.

Researchers

Presenter

  • Sherise C Rogers

Principal Investigators

  • Christine Ann Garcia

  • Shenhong Wu

Medical Centers

  • Stony Brook University, Stony Brook, NY

  • Stony Brook University Hospital, Port Jefferson, NY

  • Stony Brook University School of Medicine, Stony Brook, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved